1.48
-0.01(-0.67%)
Currency In USD
| Previous Close | 1.49 |
| Open | 1.49 |
| Day High | 1.5 |
| Day Low | 1.43 |
| 52-Week High | 2.68 |
| 52-Week Low | 1 |
| Volume | 1.76M |
| Average Volume | 2.05M |
| Market Cap | 233.75M |
| PE | -16.44 |
| EPS | -0.09 |
| Moving Average 50 Days | 1.23 |
| Moving Average 200 Days | 1.62 |
| Change | -0.01 |
If you invested $1000 in Heron Therapeutics, Inc. (HRTX) 10 years ago, it would be worth $63.74 as of January 14, 2026 at a share price of $1.48. Whereas If you bought $1000 worth of Heron Therapeutics, Inc. (HRTX) shares 5 years ago, it would be worth $80.7 as of January 14, 2026 at a share price of $1.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
GlobeNewswire Inc.
Jan 09, 2026 2:29 PM GMT
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We ar
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
GlobeNewswire Inc.
Dec 04, 2025 1:15 PM GMT
APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or adde
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
GlobeNewswire Inc.
Oct 29, 2025 9:58 PM GMT
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has e